Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month Low Following Analyst Downgrade

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price hit a new 52-week low on Friday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The stock traded as low as $28.90 and last traded at $29.11, with a volume of 2131636 shares traded. The stock had previously closed at $35.74.

Other equities research analysts have also issued reports about the company. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Needham & Company LLC decreased their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a research note on Thursday. Piper Sandler reiterated a “neutral” rating and issued a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday. Finally, Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $52.60.

Collegium Pharmaceutical News Summary

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Second-quarter adjusted EPS was $1.92, above analyst expectations of approximately $1.72, while revenue increased 6.3% year over year to $199.9 million. Adjusted EBITDA rose 8% to $113.8 million and operating cash flow was $71.3 million. Collegium Pharmaceutical Q2 Earnings Beat
• Positive Sentiment: The ADHD portfolio showed momentum: JORNAY PM revenue climbed 41% to $46.1 million, and the completed AZSTARYS acquisition contributed $12.9 million in partial-quarter revenue. Collegium raised its full-year AZSTARYS revenue outlook to $65 million-$75 million from $60 million-$70 million, potentially supporting longer-term growth. Collegium Q2 2026 Results
• Neutral Sentiment: Piper Sandler reaffirmed its “neutral” rating but lowered its price target to $43 from $45. Needham retained a “buy” rating while cutting its target to $46 from $56, reflecting continued upside but greater near-term caution. Analyst Price Target Updates
• Negative Sentiment: Collegium reduced full-year product-revenue guidance to $825 million-$855 million from $865 million-$895 million and lowered adjusted EBITDA guidance to $445 million-$470 million from $475 million-$500 million. The company cited lower pricing and weaker-than-expected authorized-generic Nucynta revenue.
• Negative Sentiment: The pain portfolio declined 9% year over year to $140.9 million; Nucynta revenue fell 24% and Xtampza ER revenue dropped 14%. GAAP results also shifted to a $15.1 million net loss from $12.0 million of net income, while operating expenses increased 45%, adding pressure to profitability. Collegium Sales and Guidance Report

Institutional Trading of Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in the company. Group One Trading LLC bought a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 427 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $61,000. PNC Financial Services Group Inc. grew its position in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 418 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 318 shares during the last quarter.

Collegium Pharmaceutical Price Performance

The stock has a fifty day moving average of $34.78 and a two-hundred day moving average of $37.07. The company has a current ratio of 1.14, a quick ratio of 1.62 and a debt-to-equity ratio of 3.50. The stock has a market capitalization of $955.83 million, a price-to-earnings ratio of 23.77 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The business’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.68 earnings per share. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.